Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 67.95 percent increase over losses of $(0.78) per share from the same period last year.